Correlation Between Neurocrine Biosciences and Aurora Cannabis

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and Aurora Cannabis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and Aurora Cannabis into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurocrine Biosciences and Aurora Cannabis, you can compare the effects of market volatilities on Neurocrine Biosciences and Aurora Cannabis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of Aurora Cannabis. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and Aurora Cannabis.

Diversification Opportunities for Neurocrine Biosciences and Aurora Cannabis

-0.72
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Neurocrine and Aurora is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and Aurora Cannabis in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aurora Cannabis and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with Aurora Cannabis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aurora Cannabis has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and Aurora Cannabis go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and Aurora Cannabis

Given the investment horizon of 90 days Neurocrine Biosciences is expected to generate 0.46 times more return on investment than Aurora Cannabis. However, Neurocrine Biosciences is 2.18 times less risky than Aurora Cannabis. It trades about 0.13 of its potential returns per unit of risk. Aurora Cannabis is currently generating about -0.12 per unit of risk. If you would invest  11,835  in Neurocrine Biosciences on September 20, 2024 and sell it today you would earn a total of  1,661  from holding Neurocrine Biosciences or generate 14.03% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Neurocrine Biosciences  vs.  Aurora Cannabis

 Performance 
       Timeline  
Neurocrine Biosciences 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent forward indicators, Neurocrine Biosciences showed solid returns over the last few months and may actually be approaching a breakup point.
Aurora Cannabis 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Aurora Cannabis has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Neurocrine Biosciences and Aurora Cannabis Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neurocrine Biosciences and Aurora Cannabis

The main advantage of trading using opposite Neurocrine Biosciences and Aurora Cannabis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, Aurora Cannabis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aurora Cannabis will offset losses from the drop in Aurora Cannabis' long position.
The idea behind Neurocrine Biosciences and Aurora Cannabis pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing